Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase

Blood

Volumn 87, Issue 6, 1996, Pages 2337-2344

  Jansen, Patty M ^a   Pixley, Robin A ^b   Brouwer, Mieke ^b   De Jong, Irma W ^b   Chang, Alvin C K ^b   Hack, C Erik ^b   Taylor Jr , Fletcher B ^b   Colman, Robert W ^b  

^a CENTRAL LABORATORY   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12; INTERLEUKIN 6; LEUKOCYTE ELASTASE;

ANIMAL MODEL; ARTICLE; BABOON; COMPLEMENT ACTIVATION; ENZYME INHIBITION; FIBRINOLYSIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPSIS;

EID: 0029986326     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.6.2337.bloodjournal8762337     Document Type: Article

References (73)

1. de la Cadena RA, Wachtfogel YT, Colman RW: Contact activation pathway: Inflammation and coagulation, in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA, Lippincott, 1993, p 219
2. Kaplan AP, Austen KF: A prealbumin activator of prekallikrein. J Immunol 105:802, 1970
3. Kaplan AP, Austen KF: A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133:696, 1971
4. Pierce TV: Structural features of plasma kinins and kininogens. Fed Proc 27:52, 1968
5. Davie EW, Fujikawa K, Kurachi K: The role of serine proteases in the blood coagulation cascade. Adv Enzymol 48:227, 1979
6. Morrison DC, Cochrane CG: Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 140:797, 1974
7. Colman RW, Edelman R, Scott CF, Gilman RM: Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest 61:287, 1978
8. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, Abbink JJ, Strack van Schijndel RJM, Felt-Bersma RJF, Thijs LG, Hack CE: Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood 72:1841, 1988
9. Mason JM, Kleeberg V, Dolan P, Colman RW: Plasma kallikrein and Hageman factor in gram-negative bacteremia. Ann Intern Med 73:545, 1970
10. Robinson JA, Klodynicky ML, Loeb HS, Recic MR, Gunnar RM: Endotoxin, prekallikrein, complement, and systemic vascular resistance. Sequential measurements in man. Am J Med 59:61, 1975
11. Hack CE, Nuijens JH, Strack van Schijndel RJM, Abbink JJ, Eerenberg AJM, Thijs LG: A model for the interplay of inflammatory mediators in sepsis - A study in 48 patients. Intens Care Med 16:8187, 1990 (suppl 3)
12. Toda N, Okamura T: Endothelium-dependent and independent response to vasoactive substances of isolated human coronary artery. Am J Physiol 262:H995, 1992
13. Hong SL: Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res 18:787, 1980
14. Pixley RA, de la Cadena R, Page JD, Kaufman N, Wyshock EG, Colman RW, Chang A, Taylor FB Jr: Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 140:897, 1992
15. Pixley RA, de la Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FB Jr, Colman RW: The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 91:61, 1993
16. Shapiro L, Gelfand JA: Cytokines and sepsis: Pathophysiology and therapy. New Horiz 1:13, 1993
17. Hack CE, Nuijens JH, Felt-Bersma RJF, Schreuder WO, Eerenberg-Belmer AJM, Paardekooper J, Bronsveld W, Thijs LG: Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 86:20, 1989
18. McCabe WR: Serum complement levels in bacteremia due to gram-negative organisms. N Engl J Med 288:21, 1973
19. Hesselvik JF, Blomback M, Brodin B, Maller R: Coagulation, fibrinolysis, and kallikrein systems in sepsis: Relation to outcome. Crit Care Med 17:724, 1989
20. Duswald KH, Jochum M, Schramm W, Fritz H: Released granulocytic elastase: An indicator of pathobiochemical alterations in septicaemia after abdominal surgery. Surgery 98:892, 1985
21. Egbring R, Schmidt W, Fuchs G, Havermann K: Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 49:219, 1977
22. 1-antitrypsin and lactoferrin in sepsis: Evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 119:159, 1992
23. Toossi Z, Sedor JR, Mettler MA, Everson B, Young T. Ratnoff OD: Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). Proc Natl Acad Sci USA 89:11969, 1992
24. Chien P, Pixley RA, Stumpo LG, Colman RW, Schreiber AD: Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor. J Clin Invest 82:1554, 1988
25. Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M, Cohen AB, Colman RW: Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 72:1672, 1983
26. Ghebrehiwet B, Silverberg M, Kaplan AP: Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 153:665, 1981
27. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP: Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 71:1450, 1983
28. Cooper NR, Miles LA, Griffin JH: Effects of plasma kallikrein and plasmin on the first complement component. J Immunol 124:1517, 1980 (abstr)
29. DiScipio RG: The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 45:587, 1982
30. Kluft C, Dooijewaard G, Emeis JJ: Role of the contact system in fibrinolysis. Semin Thromb Hemost 13:50, 1987
31. Creasey AA, Stevens P, Kenney J, Allison AC, Warren K, Catlett R, Hinshaw L, Taylor FB Jr: Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock 33:84, 1991
32. Hinshaw LB, Brackett DJ, Archer LT, Beller BK, Wilson MF: Detection of the "hyperdynamic state" of sepsis in the baboon during lethal E. coli infusion. J Trauma 23:361, 1983
33. Hack CE, Paardekooper J, Smeenk RJT, Abbink JJ, Eerenberg AJM, Nuijens JH: Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3. An analysis with monoclonal antibodies. J Immunol 141:1602, 1988
34. Hack CE, Paardekooper J, van Milligen F: Demonstration in human plasma of a form of C3 that has the conformation of "C3b-like C3." J Immunol 144:4249, 1990
35. Wolbink GJ, Bollen J, Baars JW, ten Berge RJM, Swaak AJG, Paardekooper J, Hack CE: Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 163:67, 1993
36. Hack CE, Hannema AJ, Eerenberg-Belmer AJM, Out TA, Aalberse RC: A C1-inhibitor-complex assay (INCA): A method to detect C1 activation in vitro and in vivo. J Immunol 127:1450, 1981
37. de Boer JP, Creasey AA, Chang A, Roem D, Brouwer MC, Eerenberg AJM, Hack CE, Taylor FB Jr: Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of E coli. Circ Shock 39:59, 1993
38. Boermeester MA, van Leeuwen PAM, Coyle SM, Wolbink GJ, Hack CE, Lowry SF: Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg 130:739, 1995
39. 2-antiplasmin complexes with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 67:111, 1992
40. Jansen PM, van Damme J, Put W, de Jong IW, Taylor FB Jr, Hack CE: Monocyte chemotactic protein 1 (MCP-1) is released during lethal and sublethal bacteremia in baboons. J Infect Dis 171:1640, 1995
41. Helle M, Boeije L, de Groot ER, de Vos A, Aarden LA: Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: Synovial fluids and sera. J Immunol Methods 138:47, 1991
42. 2 in sepsis: Studies in nonhuman primates after interleukin-1α administration and during lethal bacteremia. Blood 86:1027, 1995
43. Morrison DC, Kline LF: Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol 118:362, 1977
44. Grossman N, Leive L: Complement activation via the alternative pathway by purified salmonella lipopolysaccharide is affected by its structure but not its O-antigen length. J Immunol 132:376, 1984
45. Müller-Eberhard HJ, Schreiber RD: Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol 29:1, 1980
46. de Boer JP, Creasey AA, Chang A, Roem D, Eerenberg AJM, Hack CE, Taylor FB Jr: Activation of the complement system in baboons challenged with live E. coli: Correlation with mortality and evidence for a biphasic activation pattern. Infect Immun 61:4293, 1993
47. Wiggins RC, Giglas PC, Henson PM: Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med 153:1391, 1981
48. Suffredini AF, Harpel PC, Parillo JE: Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 18:1165, 1989
49. van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76:2520, 1990
50. van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322:1622, 1990
51. van der Poll T, Levi M, Büller HR, van Deventer SJH, de Boer JP, Hack CE, ten Cate JW: Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174:729, 1991
52. Goldsmith G, Saito H, Ratnoff OD: The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J Clin Invest 12:54, 1978
53. Mandle RJ Jr, Kaplan AP: Hageman-factor-dependent fibrinolysis: Generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood 54:850, 1979
54. Colman RW: Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 35:273, 1969
55. Ichinose A, Fujikawa K, Syama T: The activation of prourokinase by kallikrein and its inactivation by thrombin. J Biol Chem 261:3486, 1986
56. Hauert J, Nicoloso G, Schleuning WD, Bachmann F, Schapira M: Plasminogen activators in dextran sulfate-activated euglobulin fractions: A molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. Blood 73:994, 1989
57. Miles LA, Rothschild Z, Griffin JH: Dextran sulfate-dependent fibrinolysis in whole human plasma. J Lab Clin Med 101:214, 1983
58. Binnema DJ, Dooijewaard G, van Iersel JJL, Turion PNC, Kluft C: The contact-system dependent plasminogen activator from human plasma: Identification and characterization. Thromb Haemost 64:390, 1990
59. Smith O, Gilbert M, Owen WG: Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66:835, 1985
60. Emeis JJ: Perfused rat hindlegs. A model to study plasminogen activator release. Thromb Res 30.195, 1983
61. Levi M, Hack CE, de Boer JP, Brandjes DPM, Büller HR, ten Cate JW: Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest 88:1155, 1991
62. 3-antiplasmin complex levels in hereditary angioedema: Evidence for the in vivo efficiency of the intrinsic fibrinolytic system. Thromb Res 40:817, 1985
63. Cugno M, Hack CE, de Boer JP, Eerenberg AJM, Agostini A, Cicardi M: Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med 121:38, 1993
64. Kaplan AP, Kay AB, Austen KF: A prealbumin activator of prekallikrein III. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med 135:81, 1972
65. Schapira M, Despland E, Scott CF, Boxer LA, Colman RW: Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 69:1191, 1982
66. Goetzl EJ, Austen KF: Stimulation of human neutrophil aerobic glucose metabolism by purified chemotactic factors. J Clin Invest 53:591, 1974
67. Vogt W: Anaphylatoxins: Possible roles in disease. Complement 3:177, 1986
68. Mannion BA, Weiss J, Elsbach P: Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J Clin Invest 85:853, 1990
69. Evans TJ, Carpenter A, Moyes D, Martin R, Cohen J: Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis. J Infect Dis 171:153, 1995
70. van Deventer SJH, Büller HR, ten Cate JW, Sturk A, Pauw W: Endotoxaemia: An early predictor of septicaemia in febrile patients. Lancet 1:605, 1988
71. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771, 1993
72. Ratnoff OD, Voytus JA, Toossi Z: Inhibition of expression of monocyte interleukin-1 by inhibitors of Hageman factor (factor XII). J Lab Clin Med 125:247, 1995
73. Stevens JH, O'Hanley P, Schapiro JM, Mihm FG, Satoh PS, Collins JA, Raffin TA: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 77:1812, 1986